Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
These medications carry an FDA boxed warning for medullary thyroid carcinoma and are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2
Wegovy and Zepbound are FDA approved for weight loss, and Wegovy additionally received approval from the agency to treat cardiovascular conditions in patients with overweight or obesity in March
These effects typically resolve within days and may reflect immune system modulation during the adjustment period
Public docket FDA-2025-N-6895: Open for written comments through July 22, 2026, the day before the meeting convenes
